{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:21:54Z","timestamp":1791408114657,"version":"4.3.3"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013741","name":"Royal Australian and New Zealand College of Radiologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jtho.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:51:39Z","timestamp":1653817899000},"page":"961-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective"],"prefix":"10.1016","volume":"17","author":[{"given":"Nicholas W.","family":"Bucknell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard G.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.05.003_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jtho.2022.05.003_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.05.003_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.05.003_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.05.003_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib8","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-comet): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2022.05.003_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtho.2022.05.003_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11764-021-01024-8","article-title":"Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy","volume":"15","author":"Lai-Kwon","year":"2021","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.jtho.2022.05.003_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable Stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semradonc.2020.11.006","article-title":"Biology of radiation-induced lung injury","volume":"31","author":"Roy","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: current evidence","volume":"21","author":"Arroyo-Hern\u00e1ndez","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtho.2022.05.003_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib19","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ijrobp.2017.06.250","article-title":"Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy\u00a0+\/\u2212 cetuximab for stage III NSCLC","volume":"99","author":"Bradley","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for Stage III non\u2013small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fonc.2019.00877","article-title":"Radiation-induced lung injury (RILI)","volume":"9","author":"Giuranno","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1186\/s12885-019-6392-8","article-title":"Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13014-020-01654-9","article-title":"Radiation-induced lung toxicity \u2013 cellular and molecular mechanisms of pathogenesis, management, and literature review","volume":"15","author":"K\u00e4smann","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2017.04.017","article-title":"Dose to heart substructures is associated with non-cancer death after SBRT in stage I\u2013II NSCLC patients","volume":"123","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2017.09.004","article-title":"Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy","volume":"125","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijrobp.2018.12.044","article-title":"Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature","volume":"104","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1040-8428(01)00227-X","article-title":"Radiation-associated cardiovascular disease","volume":"45","author":"Adams","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2022.05.003_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/096721099600400221","article-title":"Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis","volume":"4","author":"Chello","year":"1996","journal-title":"Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2022.05.003_bib30","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtho.2022.05.003_bib31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2018.11.036","article-title":"Chest wall toxicity after stereotactic body radiation therapy: a pooled analysis of 57 studies","volume":"103","author":"Ma","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2021.06.028","article-title":"Delivered dose-effect analysis of radiation induced rib fractures after thoracic SBRT","volume":"162","author":"Juan-Cruz","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib35","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non\u2013small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","article-title":"Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for Stage III non-small cell lung cancer: CALGB 31102 (Alliance)","volume":"101","author":"Urbanic","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib37","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter Phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib39","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A\u00a0systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2022.05.003_bib41","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2020.05.051","article-title":"Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy","volume":"150","author":"Chen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib43","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180390","article-title":"Review of risk factors of secondary cancers among cancer survivors","volume":"92","author":"Demoor-Goldschmidt","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jtho.2022.05.003_bib44","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijrobp.2017.04.022","article-title":"Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma","volume":"99","author":"Vogel","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for\u00a0Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2022.05.003_bib47","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/sj.bjc.6602084","article-title":"Radiation-induced malignancies following radiotherapy for breast cancer","volume":"91","author":"Roychoudhuri","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib48","article-title":"The impact of smoking on adjuvant breast cancer radiation treatment: a systematic review","volume":"24","author":"Wong","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtho.2022.05.003_bib49","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157488712799363235","article-title":"Esophagitis, treatment-related toxicity in non-small cell lung cancer","volume":"7","author":"Bar-Ad","year":"2012","journal-title":"Rev Recent Clin Trials"},{"issue":"suppl","key":"10.1016\/j.jtho.2022.05.003_bib52","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","article-title":"Radiation dose-volume effects in the spinal cord","volume":"76","author":"Kirkpatrick","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib53","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.cllc.2020.02.025","article-title":"Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable Stage III non\u2013small-cell lung cancer","volume":"21","author":"Naidoo","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662954","article-title":"Radiation recall pneumonitis after treatment with checkpoint blockade immunotherapy: a case series and review of literature","volume":"11","author":"Riviere","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s11136-018-1834-3","article-title":"Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study","volume":"27","author":"Yue","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jtho.2022.05.003_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2016.07.025","article-title":"Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice","volume":"121","author":"Driessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgo.2013.04.002","article-title":"Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment","volume":"4","author":"Ramjaun","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.critrevonc.2017.03.031","article-title":"Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: a systematic review","volume":"114","author":"Driessen","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2022.05.003_bib60","doi-asserted-by":"crossref","first-page":"j1744","DOI":"10.1136\/bmj.j1744","article-title":"Implementing shared decision making in the NHS: lessons from the MAGIC programme","volume":"357","author":"Joseph-Williams","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jtho.2022.05.003_bib62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2011.03.012","article-title":"Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy","volume":"81","author":"De Ruyck","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.21037\/tlcr.2017.09.12","article-title":"Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy","volume":"6","author":"De Ruysscher","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2022.05.003_bib64","first-page":"1","article-title":"Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity","volume":"18","author":"Talbot","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib65","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jtho.2020.11.008","article-title":"Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC","volume":"16","author":"Scott","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A\u00a0gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A\u00a0genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib68","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.32598","article-title":"Radioresistance of KRAS\/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in\u00a0vivo","volume":"147","author":"Gurtner","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib69","doi-asserted-by":"crossref","first-page":"258","DOI":"10.18632\/oncoscience.468","article-title":"TP53 mutation status: emerging biomarker for precision radiation medicine?","volume":"5","author":"Willers","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.jtho.2022.05.003_bib70","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2016.11.002","article-title":"A\u00a0histologic basis for the efficacy of SBRT to the lung","volume":"12","author":"Woody","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib71","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2589-7500(19)30058-5","article-title":"An image-based deep learning framework for individualising radiotherapy dose","volume":"1","author":"Lou","year":"2019","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jtho.2022.05.003_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0360-3016(91)90168-4","article-title":"Dose-volume histograms","volume":"21","author":"Drzymala","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib73","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2018.11.028","article-title":"Organs at risk considerations for thoracic stereotactic body radiation therapy: what is safe for lung parenchyma?","volume":"110","author":"Kong","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"10.1016\/j.jtho.2022.05.003_bib74","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","article-title":"QA makes a clinical trial stronger: evidence-based medicine in radiation therapy","volume":"105","author":"Weber","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib76","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ijrobp.2020.11.040","article-title":"Isotoxic intensity modulated radiation therapy in Stage III non-small cell lung cancer: a feasibility study","volume":"109","author":"Haslett","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib77","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.21037\/tlcr-20-627","article-title":"Challenges in the target volume definition of lung cancer radiotherapy","volume":"10","author":"Mercieca","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2022.05.003_bib78","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170036","article-title":"Effect of accurate heart delineation on cardiac dose during the CONVERT trial","volume":"90","author":"Groom","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jtho.2022.05.003_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.radonc.2009.08.040","article-title":"4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins","volume":"93","author":"Hof","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","article-title":"Errors and margins in radiotherapy","volume":"14","author":"van Herk","year":"2004","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib81","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00066-012-0129-9","article-title":"Dosimetric comparison of free-breathing and deep inspiration breath-hold radiotherapy for lung cancer","volume":"188","author":"Marchand","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jtho.2022.05.003_bib82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.semradonc.2009.11.003","article-title":"Adaptive radiotherapy for lung cancer","volume":"20","author":"Sonke","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib83","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.ijrobp.2012.07.454","article-title":"Acute radiation pneumonitis in non-small cell lung cancer: is respiratory-gated control useful? Results of a French prospective randomized study","volume":"84","author":"Claude","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib84","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.radonc.2017.11.002","article-title":"Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: results from the Gating 2006 trial","volume":"126","author":"Jouglar","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib85","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1118\/1.4943564","article-title":"Benefits of adaptive radiation therapy in lung cancer as a function of replanning frequency","volume":"43","author":"Dial","year":"2016","journal-title":"Med Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","article-title":"Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose","volume":"121","author":"M\u00f8ller","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib87","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jtho.2017.03.025","article-title":"Local control and toxicity of adaptive radiotherapy using weekly CT imaging: results from the LARTIA trial in Stage III NSCLC","volume":"12","author":"Ramella","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib88","author":"Kong"},{"key":"10.1016\/j.jtho.2022.05.003_bib89","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.radonc.2018.07.014","article-title":"Functional lung imaging in radiation therapy for lung cancer: a systematic review and meta-analysis","volume":"129","author":"Bucknell","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib91","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/mp.12308","article-title":"Functional lung avoidance and response-adaptive escalation (FLARE) RT: multimodality plan dosimetry of a precision radiation oncology strategy","volume":"44","author":"Lee","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib92","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1186\/1471-2407-14-934","article-title":"Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial","volume":"14","author":"Hoover","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2022.05.003_bib93","doi-asserted-by":"crossref","first-page":"E507","DOI":"10.1016\/j.ijrobp.2017.06.1815","article-title":"Functional lung avoidance for individualized radiation therapy (FLAIR): study protocol for a randomized, double-blind clinical trial","volume":"99","author":"Hoover","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2015.11.006","article-title":"The first patient treatment of computed tomography ventilation functional image-guided radiotherapy for lung cancer","volume":"118","author":"Yamamoto","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042465","article-title":"Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET\/CT to avoid functional lung in patients with stage III non-small cell lung cancer","volume":"10","author":"Bucknell","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtho.2022.05.003_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200137","article-title":"Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and\/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma","volume":"13","author":"Gupta","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2022.05.003_bib97","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.radonc.2017.10.001","article-title":"Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer","volume":"125","author":"Wang","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib98","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib99","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.radonc.2022.02.010","article-title":"Major adverse cardiac event risk prediction model incorporating baseline Cardiac disease, Hypertension, and Logarithmic Left anterior descending coronary artery radiation dose in lung cancer (CHyLL)","volume":"169","author":"Tjong","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib101","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ijrobp.2021.03.005","article-title":"Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy","volume":"110","author":"Atkins","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib102","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ijrobp.2015.03.018","article-title":"A\u00a0contralateral esophagus-sparing technique to limit severe esophagitis associated with concurrent high-dose radiation and chemotherapy in patients with thoracic malignancies","volume":"92","author":"Al-Halabi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.05.003_bib103","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2021.0281","article-title":"Assessment of a contralateral esophagus-sparing technique in locally advanced lung cancer treated with high-dose chemoradiation: a Phase 1 nonrandomized clinical trial","volume":"7","author":"Kamran","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib104","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/1754-9485.13036","article-title":"Particle therapy toxicity outcomes: a systematic review","volume":"64","author":"Hwang","year":"2020","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jtho.2022.05.003_bib105","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618783878","article-title":"Advances in proton therapy in lung cancer","volume":"12","author":"Vyfhuis","year":"2018","journal-title":"Ther Adv Respir Dis"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:57Z","timestamp":1761562197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422002611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1556086422002611"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.05.003","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}